Nationwide Fund Advisors lifted its stake in shares of Exactech, Inc. (NASDAQ:EXAC) by 41.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,319 shares of the medical equipment provider’s stock after buying an additional 4,217 shares during the period. Nationwide Fund Advisors owned approximately 0.10% of Exactech worth $427,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Bank of Montreal Can acquired a new position in Exactech during the second quarter valued at $134,000. Russell Investments Group Ltd. lifted its position in Exactech by 13.2% during the second quarter. Russell Investments Group Ltd. now owns 47,118 shares of the medical equipment provider’s stock valued at $1,405,000 after purchasing an additional 5,485 shares during the period. Prudential Financial Inc. acquired a new position in Exactech during the second quarter valued at $359,000. AJO LP acquired a new position in Exactech during the second quarter valued at $483,000. Finally, Schwab Charles Investment Management Inc. lifted its position in Exactech by 14.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 53,918 shares of the medical equipment provider’s stock valued at $1,359,000 after purchasing an additional 6,742 shares during the period. Institutional investors and hedge funds own 64.23% of the company’s stock.
A number of research analysts recently issued reports on EXAC shares. Gabelli restated a “buy” rating on shares of Exactech in a research report on Monday, July 31st. Robert W. Baird set a $34.00 target price on shares of Exactech and gave the company a “buy” rating in a research report on Sunday, October 15th. BidaskClub upgraded shares of Exactech from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Sidoti downgraded shares of Exactech from a “buy” rating to a “neutral” rating in a research report on Monday, October 23rd. Finally, Zacks Investment Research downgraded shares of Exactech from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the stock. The stock has an average rating of “Hold” and an average target price of $42.00.
In other Exactech news, Director Fern Watts sold 1,013 shares of Exactech stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total value of $29,417.52. Following the completion of the transaction, the director now owns 4,727 shares of the company’s stock, valued at $137,272.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 28.30% of the stock is currently owned by insiders.
Exactech, Inc. (EXAC) opened at $42.20 on Monday. The stock has a market cap of $613.15, a price-to-earnings ratio of 34.88, a P/E/G ratio of 3.62 and a beta of 1.04. Exactech, Inc. has a 1 year low of $22.90 and a 1 year high of $42.55. The company has a current ratio of 4.15, a quick ratio of 2.18 and a debt-to-equity ratio of 0.06.
Exactech (NASDAQ:EXAC) last posted its earnings results on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). Exactech had a net margin of 0.18% and a return on equity of 7.29%. The business had revenue of $61.40 million for the quarter, compared to analyst estimates of $61.78 million. equities analysts anticipate that Exactech, Inc. will post 1.29 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.com-unik.info/2017/11/06/nationwide-fund-advisors-boosts-stake-in-exactech-inc-exac.html.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Want to see what other hedge funds are holding EXAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exactech, Inc. (NASDAQ:EXAC).
What are top analysts saying about Exactech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech Inc. and related companies.